{
  "docId": "019de071-38a0-778d-8d39-45a206af86ac",
  "docSlug": "8e68c7763c84d1b485e12f828c3b0d7e",
  "documentTitle": "argenx SE | Investor Day Presentation Deck | 69 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 69,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "before_after",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "Data from Phase 3 ADAPT trial; includes comparison to Phase 2 pemphigus trial findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-38a0-778d-8d39-45a206af86ac/21",
  "deckHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac",
  "deckJsonHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac.json",
  "deckAnchorHref": "/decks/019de071-38a0-778d-8d39-45a206af86ac#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.52,
        "x": 0.41,
        "y": 0.295
      },
      "kind": "chart",
      "text": "Albumin and LDL Cholesterol levels – 1st & 2nd cycles",
      "attrs": null,
      "subkind": "box",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8395d4a-d826-4d54-9782-f4e25007908c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.31,
        "x": 0.07,
        "y": 0.295
      },
      "kind": "chart",
      "text": "IgG levels – 1st cycle",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71f715c9-f9d5-4cf2-97f9-8956ca2992ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.05,
        "y": 0.77
      },
      "kind": "list",
      "text": "Potent reduction in IgG levels without decrease in albumin or increase in LDL levels; No albumin decreases observed with chronic dosing out to 34 weeks in Phase 2 pemphigus trial; Selective blockade of IgG recycling; Maintaining albumin is important.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45c6d4e3-fdcf-401a-8341-0a99f974063c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Efgartigimod Blocks IgG Binding to FcRn Without Reducing Albumin",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4de12f7-2b72-48b5-b104-b7ff6a74091d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "42b60006-6280-4e7e-8696-e78c0d78fb43",
      "evidence": "The slide compares before and after effects of Efgartigimod on IgG levels, albumin, and LDL levels.",
      "confidence": 0.8
    },
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "e50fef65-7ddc-44da-815e-8ff7af9c5d03",
      "evidence": "The slide includes a chart showing the reduction in IgG levels over time.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}